Cart
sales@molnova.com
KS-99
CAS No. 1344698-28-7
KS-99( KS99 | KS 99 )
Catalog No. M11378 CAS No. 1344698-28-7
KS-99 (KS99)?is a novel dual inhibitor of BTK and tubulin polymerization.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 873 | Get Quote |
|
| 50MG | 1782 | Get Quote |
|
| 100MG | 2250 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameKS-99
-
NoteResearch use only, not for human use.
-
Brief DescriptionKS-99 (KS99)?is a novel dual inhibitor of BTK and tubulin polymerization.
-
DescriptionKS-99 (KS99)?is a novel dual inhibitor of BTK and tubulin polymerization; interacts directly with the catalytic domain of BTK and inhibits phosphorylation at the Y223 residue and kinase activities; reduces the cell viability of MM and CD138+ cells (IC50=0.5-1 uM); inhibits the in vivo tumor growth of MM cells through the inhibition of BTK and tubulin.
-
In Vitro——
-
In Vivo——
-
SynonymsKS99 | KS 99
-
PathwayTyrosine Kinase
-
TargetBTK
-
RecptorBTK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1344698-28-7
-
Formula Weight466.147
-
Molecular FormulaC17H10Br2N2O2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1N(CC2=CC=C(CSC#N)C=C2)C3=C(C=C(Br)C=C3Br)C1=O
-
Chemical Name5,7-dibromo-1-(4-(thiocyanatomethyl)benzyl)indoline-2,3-dione
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Pandey MK, et al. Exp Hematol. 2017 Jun 22. pii: S0301-472X(17)30233-3.
molnova catalog
related products
-
Edralbrutinib
Edralbrutinib (TG-1701) is a potent BTK inhibitor with anticancer activity used in treating tumors, immune system disorders, and blood and lymphatic system disorders.
-
BTK IN-1
BTK IN-1 (SNS062 analog) is an effective BTK inhibitor (IC50: <100 nM).
-
GNE-431
GNE-431 is a potent, selective and noncovalent Btk inhibitor with IC50 of 3.2 nM and 2.5 nM for WT Btk and C481S mutant, respectively.
